CNBX (CNBX Pharmaceuticals) Total Assets : $0.02 Mil (As of Nov. 2024)

View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals Total Assets?

CNBX Pharmaceuticals's Total Assets for the quarter that ended in Nov. 2024 was $0.02 Mil.

During the past 12 months, CNBX Pharmaceuticals's average Total Assets Growth Rate was -98.40% per year. During the past 3 years, the average Total Assets Growth Rate was -85.70% per year. During the past 5 years, the average Total Assets Growth Rate was -71.40% per year. During the past 10 years, the average Total Assets Growth Rate was 32.40% per year.

During the past 13 years, CNBX Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 1226.10%. The lowest was -85.70%. And the median was 74.80%.

Total Assets is connected with ROA %. CNBX Pharmaceuticals's annualized ROA % for the quarter that ended in Nov. 2024 was -513.21%. Total Assets is also linked to Revenue through Asset Turnover. CNBX Pharmaceuticals's Asset Turnover for the quarter that ended in Nov. 2024 was 0.00.

CNBX Pharmaceuticals Total Assets Historical Data

The historical data trend for CNBX Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals Total Assets Chart

CNBX Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Total Assets

Get a 7-Day Free Trial

2.22

3.08

0.81

0.50

0.03

CNBX Pharmaceuticals Quarterly Data
	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24
Total Assets	Get a 7-Day Free Trial															0.39	0.16	0.08	0.03	0.02

CNBX Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

CNBX Pharmaceuticals's Total Assets for the fiscal year that ended in Aug. 2024 is calculated as

Total Assets	=	Total Equity (A: Aug. 2024 )	+	Total Liabilities (A: Aug. 2024 )
	=	-2.48	+	2.511
	=	0.03

CNBX Pharmaceuticals's Total Assets for the quarter that ended in Nov. 2024 is calculated as

Total Assets	=	Total Equity (Q: Nov. 2024 )	+	Total Liabilities (Q: Nov. 2024 )
	=	-2.514	+	2.537
	=	0.02

CNBX Pharmaceuticals (OTCPK:CNBX) Total Assets Explanation

Total Assets is connected with ROA %.

CNBX Pharmaceuticals's annualized ROA % for the quarter that ended in Nov. 2024 is

ROA %	=	Net Income (Q: Nov. 2024 )	/	( (Total Assets (Q: Aug. 2024 )	+	Total Assets (Q: Nov. 2024 ))	/ count )
	=	-0.136	/	( (0.031	+	0.022)	/ 2 )
	=	-0.136	/	0.0265
	=	-513.21 %

Note: The Net Income data used here is four times the quarterly (Nov. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

CNBX Pharmaceuticals's Asset Turnover for the quarter that ended in Nov. 2024 is

	Asset Turnover
=	Revenue (Q: Nov. 2024 )	/	( (Total Assets (Q: Aug. 2024 )	+	Total Assets (Q: Nov. 2024 ))	/ count )
=	0	/	( (0.031	+	0.022)	/ 2 )
=	0	/	0.0265
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

CNBX Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

CNBX Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814

Website

https://www.cnbxpharma.com

CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.

Executives

Cannabics Inc.	10 percent owner	108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills	director, officer: President, CEO, CFO
North American Mining Corp	10 percent owner	6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford	director, officer: Vice-President, Secretary